77 Myocardial fibrosis in esophageal cancer patients [32]Hardenbergh PH, Munley MT, Bentel GC, Kedem R, Borges-Neto S, Hollis D, et al. Cardiac perfusion changes in patients treated for breast cancer with radiation therapy and doxorubicin: Preliminary results. Int J Radiat Oncol Biol Phys 2001;49:1023–8. https://doi.org/10.1016/S03603016(00)01531-5. [33]Marks LB, Yu X, Prosnitz RG, Zhou SM, Hardenbergh PH, Blazing M, et al. The incidence and functional consequences of RT-associated cardiac perfusion defects. Int J Radiat Oncol Biol Phys 2005;63:214–23. https://doi.org/10.1016/j.ijrobp.2005.01.029. [34]Gayed IW, Liu HH, Yusuf SW, Komaki R, Wei X, Wang X, et al. The prevalence of myocardial ischemia after concurrent chemoradiation therapy as detected by gated myocardial perfusion imaging in patients with esophageal cancer. J Nucl Med 2006;47:1756–62. [35]VEINOT J. Pathology of radiation-induced heart disease: A surgical and autopsy study of 27 cases. Hum Pathol 2004;27:766–73. https://doi.org/10.1016/s0046-8177(96)90447-5. [36]Van Nimwegen FA, Schaapveld M, Cutter DJ, Janus CPM, Krol ADG, Hauptmann M, et al. Radiation dose-response relationship for risk of coronary heart disease in survivors of Hodgkin lymphoma. J Clin Oncol 2016;34:235–43. https://doi.org/10.1200/JCO.2015.63.4444. [37]Darby SC, Ewertz M, McGale P, Bennet AM, Blom-Goldman U, Brønnum D, et al. Risk of ischemic heart disease in women after radiotherapy for breast cancer. N Engl J Med 2013;368:987–98. https://doi.org/10.1056/NEJMoa1209825. [38]Cerqueira MD, Weissman NJ, Dilsizian V, Jacobs AK, Kaul S, Laskey WK, et al. Standardized myocardial segmentation and nomenclature for tomographic imaging of the heart. A statement for healthcare professionals from the Cardiac Imaging Committee of the Council on Clinical Cardiology of the American Heart Association. Int J Cardiovasc Imaging 2002;18:539–42. [39]Cerci RJ, Arbab-Zadeh A, George RT, Miller JM, Vavere AL, Mehra V, et al. Aligning coronary anatomy and myocardial perfusion territories an algorithm for the core320 multicenter study. Circ Cardiovasc Imaging 2012;5:587–95. https://doi.org/10.1161/CIRCIMAGING.111.970608. [40] Mezzaroma E, Di X, Graves P, Toldo S, Van Tassell BW, Kannan H, et al. A mouse model of radiation-induced cardiomyopathy. Int J Cardiol 2012;156:231–3. https://doi.org/10.1016/j. ijcard.2012.01.038. [41] Lurz JA, Luecke C, Lang D, Besler C, Rommel KP, Klingel K, et al. CMR–Derived Extracellular Volume Fraction as a Marker for Myocardial Fibrosis: The Importance of Coexisting Myocardial Inflammation. JACC Cardiovasc Imaging 2018;11:38–45. https://doi.org/10.1016/j. jcmg.2017.01.025. [42]Shiraishi Y, Xu C, Yang J, Komaki R, Lin SH. Dosimetric comparison to the heart and cardiac substructure in a large cohort of esophageal cancer patients treated with proton beam therapy or Intensity-modulated radiation therapy. Radiother Oncol 2017;125:48–54. https:// doi.org/10.1016/j.radonc.2017.07.034. [43]Fang L, Murphy AJ, Dart AM. A clinical perspective of anti-fibrotic therapies for cardiovascular disease. Front Pharmacol 2017;8:1–8. https://doi.org/10.3389/fphar.2017.00186. 5
RkJQdWJsaXNoZXIy MTk4NDMw